Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Fishes For Urology Growth, Lands TUNA BPH Device With VidaMed

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's $326 mil. acquisition of VidaMed is expected to close in January 2002, just as Medicare reimbursement for the firm's transurethral needle ablation (TUNA) system for benign prostatic hyperplasia (BPH) increases from $2,455 per procedure to $3,043

You may also be interested in...



Celsion Looking At Sale Of BPH Business, Will Shift Focus To Cancer Unit

Celsion is planning to submit a PMA for its Adaptive Phased Array (APA) breast cancer treatment by late 2003, while the company also considers the sale of its benign prostatic hypertrophy business

Celsion Looking At Sale Of BPH Business, Will Shift Focus To Cancer Unit

Celsion is planning to submit a PMA for its Adaptive Phased Array (APA) breast cancer treatment by late 2003, while the company also considers the sale of its benign prostatic hypertrophy business

Urologix March Stock Price Gain Propelled By BPH Systems, Disposables

Increased market penetration and improved reimbursement rates for Urologix, Inc.'s Targis Cooled ThermoTherapy system for treatment of benign prostatic hyperplasia (BPH) translated into a nearly 30% stock price gain in March. The issue advanced $4.17 to close at $18.17 for the month

Related Content

UsernamePublicRestriction

Register

MT015819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel